Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
SB3081, titled the Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025, would create a new federal pathway for certain drugs, biological products, and medical devices that are already authorized for lawful marketing in specified foreign countries or the United Kingdom. Under the bill, a sponsor could request “reciprocal marketing approval” from the Secretary of Health and Human Services, and the product would be treated much like one that has already received FDA approval or clearance under existing pathways for drugs, devices, and biologics.
The bill requires the sponsor to show that the product is not already approved in the United States, is not subject to a safety- or effectiveness-based withdrawal, is not a banned device, and meets a U.S. public health or unmet medical need. The Secretary would have 30 days to grant or deny the request, could deny approval based on affirmative safety or effectiveness concerns, and could impose postmarket study requirements. The bill also requires English translations of foreign authorization dossiers, directs FDA to negotiate labeling during the review period, and sets up monthly reporting to Congress on denials.
If enacted, SB3081 would amend the Federal Food, Drug, and Cosmetic Act by adding a new section 524C establishing reciprocal marketing approval for covered products. It would effectively create a faster, foreign-authorization-based route into the U.S. market for qualifying drugs, biologics, and devices, while making those products subject to the same general provisions, fees, labeling requirements, and postmarket oversight that apply to products approved through existing FDA pathways. It would also require FDA outreach to encourage sponsors to seek this approval and would allow Congress to disapprove FDA denials through a joint resolution process.
Based on the bill text and the absence of recorded committee discussion or votes in the provided materials, the overall sentiment appears supportive of faster access to treatments and devices that have already been vetted abroad. The bill’s title and structure suggest a pro-access, pro-innovation approach aimed at reducing delays for potentially lifesaving products. At the same time, the inclusion of safety screens, postmarket study authority, and congressional disapproval procedures indicates an effort to balance expedited access with oversight.
The main points of contention are likely to center on whether foreign regulatory approvals should be sufficient to justify U.S. market access, how much discretion FDA should retain to reject products, and whether the 30-day decision timeline is too short for meaningful review. Supporters would likely emphasize faster access, reduced duplication, and treatment of unmet medical needs, while critics may worry about differences in foreign standards, patient safety, labeling adequacy, and the potential for Congress to override FDA denials. No specific committee objections or vote-based divisions are provided in the materials.